Needham Remains a Buy on KalVista Pharmaceuticals Inc (KALV)

By Jason Carr

In a report released today, Serge Belanger from Needham maintained a Buy rating on KalVista Pharmaceuticals Inc (KALVResearch Report), with a price target of $35.00. The company’s shares closed last Monday at $11.08, close to its 52-week low of $9.86.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -2.7% and a 40.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Flexion Therapeutics.

Currently, the analyst consensus on KalVista Pharmaceuticals Inc is a Strong Buy with an average price target of $31.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $34.92 and a one-year low of $9.86. Currently, KalVista Pharmaceuticals Inc has an average volume of 127.1K.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KALV in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME).